88568-95-0

Basic information

• Product Name: (+/-)-BENZYLOXYCARBONYL-ALPHA-PHOSPHONOGLYCINE TRIMETHYL ESTER
• Synonyms: 2-(DiMethoxyphosphinyl)-2-[[(benzyloxy)carbonyl]aMino]acetic acid Methyl ester;Benzyloxycarbonyl-alpha-phosphonoglycinetriMethyl es;(+/-)-BENZYLOXYCARBONYL-ALPHA-PHOSPHONOGLYCINE;Methyl 2-(((benzyloxy)carbonyl)aMino)-2-(diMethoxyphosphoryl)acetate;Z-Gly(PO(OME2))-OMe;(±Acetic acid, 2-(dimethoxyphosphinyl)-2-[[(phenylmethoxy)carbonyl]amino]-, methyl ester;Cbz-a-phosphono-glycine trimethyl ester
• CAS NO: 88568-95-0
• Molecular Formula: C13H18NO7P
• Molecular Weight: 331.26
• EINECS: 1308068-626-2
• Mol File: 88568-95-0.mol
• Article Data: 12

Chemical Properties

• Melting Point: 77-80 °C(lit.)
• Boiling Point: 480.5 °C at 760 mmHg
• Flash Point: 244.4 °C
• Appearance: White/Crystalline Powder
• Density: 1.284 g/cm³
• Vapor Pressure: 2.16E-09mmHg at 25°C
• Refractive Index: 1.504
• Storage Temp.: 2-8°C
• Solubility: Soluble in methanol.
• PKA: 9.42±0.46(Predicted)
• BRN: 5764460
• CAS DataBase Reference: (+/-)-BENZYLOXYCARBONYL-ALPHA-PHOSPHONOGLYCINE TRIMETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-BENZYLOXYCARBONYL-ALPHA-PHOSPHONOGLYCINE TRIMETHYL ESTER(88568-95-0)
• EPA Substance Registry System: (+/-)-BENZYLOXYCARBONYL-ALPHA-PHOSPHONOGLYCINE TRIMETHYL ESTER(88568-95-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 22-24/25-36-26-37/39
• WGK Germany: 3
• Hazardous Substances Data: 88568-95-0(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

Uses

Different sources of media describe the Uses of 88568-95-0 differently. You can refer to the following data:
1. Starting material for the synthesis of (Z)-dehydroamino acids by Wittig-Horner reaction with aldehydes; the dehydroamino acids can be stereoselectively reduced to amino acids
2. Z-α-Phosphonoglycine is used in the synthesis of calcitonin gene-related peptide antagonists. Also used in the synthesis of dehydroamino acid esters for amino acid and peptide research.

InChI:InChI=1/C13H18NO7P/c1-18-12(15)11(22(17,19-2)20-3)14-13(16)21-9-10-7-5-4-6-8-10/h4-8,11H,9H2,1-3H3,(H,14,16)/t11-/m1/s1

Upstream product

• 64356-76-9 N-benzyloxycarbonyl α-chloro glycine methyl ester 
• 121-45-9 phosphorous acid trimethyl ester 
• 127357-37-3 methyl 2-(benzyloxycarbonylamino)-2-methoxyacetate 
• 79002-45-2 N-benzyloxycarbonyl-glycine 
• 621-84-1 O-benzyl carbamate 
• 127357-38-4 N-(benzyloxycarbonyl)-α-hydroxy-glycine methyl ester 

Downstream Products

• 590369-87-2 methyl 6-chloroisoquinoline-3-carboxylate 
• 1282534-50-2 methyl (2S)-2-benzyloxycarbonylamino-3-(3-quinolyl)propanoate 
• 950224-79-0 methyl β-[(2-aminophenyl)thio]-N-[(benzyloxy)carbonyl]-2,5-difluorophenylalaninate 

Relevant articles and documents

Preparation method of Wittig-Horner reagent

A preparation method of a Wittig-Horner reagent is disclosed. According to the preparation method of the Wittig-Horner reagent provided by the invention, a compound with a structure as shown in a formula (I) and a glyoxylic acid aqueous solution with a sp

SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS

The present invention relates to a series of substituted compounds having the general formula (I), including their ste reoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3. R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.

Scalable synthesis of the desoxy-biphenomycin B core

We describe the evolution of a kilogram-scale synthesis of the protected cyclic tripeptide desoxy-biphenomycin B, based on an early discovery route. The retrosynthetic concept included a macrolactamization strategy to build the core ring system of biphenomycin B in combination with a double catalytic asymmetric hydrogenation protocol for the construction of the ansa-tripeptide precursor. Eventually, the kilogram process comprised a 16-step sequence with an overall yield for the longest linear sequence of 19.5%.